IRCM, Inserm, Université Montpellier, ICM, Montpellier, France.
IRCM, Inserm, Université Montpellier, ICM, Montpellier, France
Anticancer Res. 2022 Jan;42(1):185-193. doi: 10.21873/anticanres.15472.
We hypothesized that perioperative FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) might be used as an alternative to standard FLOT (docetaxel, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with locally advanced oesogastric adenocarcinomas (OGA), particularly those with frailties.
We reviewed the charts of 61 consecutives patients treated with FOLFOX for resectable OGA to estimate overall survival, recurrence-free survival, and safety.
The median follow-up was 69.7 (range=3.6-97.9) months. Few patients experienced grade 3 adverse events during the preoperative (n=6; 10%) and postoperative (n=6; 16%) phases. One patient experienced a fatal grade 5 adverse events (cardiogenic shock). Median overall survival was 51.7 months [95% confidence interval (CI)=31.6-93.2 months] and the 5-year survival rate was 44.4% (95% CI=30.3%-57.5%).
Regarding its comparable efficacy and its favourable toxicity profile, perioperative FOLFOX is a reasonable alternative to FLOT for frail patients with resectable OGA.
我们假设围手术期 FOLFOX（5-氟尿嘧啶、亚叶酸钙、奥沙利铂）可能是局部晚期胃食管腺癌（OGA）患者的标准 FLOT（多西紫杉醇、5-氟尿嘧啶、亚叶酸钙和奥沙利铂）的替代方案，特别是对于虚弱的患者。
我们回顾了 61 例接受 FOLFOX 治疗可切除 OGA 的连续患者的病历，以估计总生存率、无复发生存率和安全性。
中位随访时间为 69.7 个月（范围=3.6-97.9 个月）。少数患者在术前（n=6；10%）和术后（n=6；16%）阶段经历了 3 级不良事件。1 例患者发生致命 5 级不良事件（心源性休克）。中位总生存期为 51.7 个月[95%置信区间（CI）=31.6-93.2 个月]，5 年生存率为 44.4%（95% CI=30.3%-57.5%）。
鉴于其可比较的疗效和良好的毒性谱，围手术期 FOLFOX 是可切除 OGA 虚弱患者的标准 FLOT 的合理替代方案。
